VERTEX PHARMACEUTICALS INC / MA Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent of -$28.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent · last filed 2026-08-04
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for the quarter ending 2026-06-30 was -$10.40M.
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for the quarter ending 2026-03-31 was -$18.00M, a 187.38% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for the quarter ending 2025-12-31 was -$26.90M, a 237.95% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for the quarter ending 2025-09-30 was -$27.30M.
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for fiscal 2025 was -$49.60M, a 291.51% decline from fiscal 2024.
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for fiscal 2024 was $25.90M, a 9.28% increase from fiscal 2023.
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for fiscal 2023 was $23.70M, a 82.99% decline from fiscal 2022.
- VERTEX PHARMACEUTICALS INC / MA reclassification from aoci, current period, net of tax, attributable to parent for fiscal 2022 was $139.30M.
| Period end | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 3 month | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 3 month as first filed | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 6 month | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 6 month as first filed | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 9 month | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 9 month as first filed | Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$10.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$28.40M 10-Q · filed 2026-08-04 | -$55.30M derived: sum of 3 quarters · filed 2026-08-04 | -$82.60M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2026-03-31 | -$18.00M 10-Q · filed 2026-05-05 | -$44.90M derived: sum of 2 quarters · filed 2026-05-05 | -$72.20M derived: sum of 3 quarters · filed 2026-05-05 | -$88.20M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-12-31 | -$26.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | -$54.20M derived: sum of 2 quarters · filed 2026-02-13 | -$70.20M derived: sum of 3 quarters · filed 2026-08-04 | -$49.60M 10-K · filed 2026-02-13 | |||
| 2025-09-30 | -$27.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$43.30M derived: sum of 2 quarters · filed 2026-08-04 | -$22.70M 10-Q · filed 2025-11-04 | -$3.20M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-06-30 | -$16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.60M 10-Q · filed 2026-08-04 | $24.10M derived: sum of 3 quarters · filed 2026-08-04 | $23.40M derived: sum of 4 quarters · filed 2026-08-04 | |||
| 2025-03-31 | $20.60M 10-Q · filed 2026-05-05 | $40.10M derived: sum of 2 quarters · filed 2026-05-05 | $39.40M derived: sum of 3 quarters · filed 2026-05-05 | $44.60M derived: sum of 4 quarters · filed 2026-05-05 | |||
| 2024-12-31 | $19.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $18.80M derived: sum of 2 quarters · filed 2026-02-13 | $24.00M derived: sum of 3 quarters · filed 2026-02-13 | $25.90M 10-K · filed 2026-02-13 | |||
| 2024-09-30 | -$700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.50M derived: sum of 2 quarters · filed 2025-11-04 | $6.40M 10-Q · filed 2025-11-04 | $4.20M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $7.10M 10-Q · filed 2025-08-05 | $4.90M derived: sum of 3 quarters · filed 2026-02-13 | $7.10M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-03-31 | $1.90M 10-Q · filed 2025-05-06 | -$300.00K derived: sum of 2 quarters · filed 2026-02-13 | $1.90M derived: sum of 3 quarters · filed 2026-02-13 | $8.40M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2023-12-31 | -$2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-13 | $0.00 derived: sum of 2 quarters · filed 2026-02-13 | $6.50M derived: sum of 3 quarters · filed 2026-02-13 | $23.70M 10-K · filed 2026-02-13 | |||
| 2023-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $8.70M derived: sum of 2 quarters · filed 2024-11-05 | $25.90M 10-Q · filed 2024-11-05 | $63.10M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-06-30 | $6.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $23.70M 10-Q · filed 2024-08-02 | $60.90M derived: sum of 3 quarters · filed 2025-02-13 | $112.00M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2023-03-31 | $17.20M 10-Q · filed 2024-05-07 | $54.40M derived: sum of 2 quarters · filed 2025-02-13 | $105.50M derived: sum of 3 quarters · filed 2025-02-13 | $140.70M derived: sum of 4 quarters · filed 2025-02-13 | |||
| 2022-12-31 | $37.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-13 | $88.30M derived: sum of 2 quarters · filed 2025-02-13 | $123.50M derived: sum of 3 quarters · filed 2025-02-13 | $139.30M 10-K · filed 2025-02-13 | |||
| 2022-09-30 | $51.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $86.30M derived: sum of 2 quarters · filed 2023-11-07 | $102.10M 10-Q · filed 2023-11-07 | $109.40M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-06-30 | $35.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $51.00M 10-Q · filed 2023-08-02 | $58.30M derived: sum of 3 quarters · filed 2024-02-15 | $54.20M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2022-03-31 | $15.80M 10-Q · filed 2023-05-02 | $23.10M derived: sum of 2 quarters · filed 2024-02-15 | $19.00M derived: sum of 3 quarters · filed 2024-02-15 | $5.30M derived: sum of 4 quarters · filed 2024-02-15 | |||
| 2021-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $3.20M derived: sum of 2 quarters · filed 2024-02-15 | -$10.50M derived: sum of 3 quarters · filed 2024-02-15 | -$23.50M 10-K · filed 2024-02-15 | |||
| 2021-09-30 | -$4.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-28 | -$17.80M derived: sum of 2 quarters · filed 2022-10-28 | -$30.80M 10-Q · filed 2022-10-28 | -$30.84M 10-Q · filed 2021-11-03 | -$40.00M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-06-30 | -$13.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | -$26.70M 10-Q · filed 2022-08-05 | -$26.74M 10-Q · filed 2021-07-30 | -$35.90M derived: sum of 3 quarters · filed 2023-02-10 | -$41.58M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2021-03-31 | -$13.00M 10-Q · filed 2022-05-06 | -$12.95M 10-Q · filed 2021-04-30 | -$22.20M derived: sum of 2 quarters · filed 2023-02-10 | -$27.88M derived: sum of 3 quarters · filed 2023-02-10 | -$22.89M derived: sum of 4 quarters · filed 2023-02-10 | ||
| 2020-12-31 | -$9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | -$14.88M derived: sum of 2 quarters · filed 2023-02-10 | -$9.89M derived: sum of 3 quarters · filed 2023-02-10 | -$2.90M 10-K · filed 2023-02-10 | |||
| 2020-09-30 | -$5.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$692.00K derived: sum of 2 quarters · filed 2021-11-03 | $6.30M 10-Q · filed 2021-11-03 | $11.95M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-06-30 | $4.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $11.98M 10-Q · filed 2021-07-30 | $17.63M derived: sum of 3 quarters · filed 2022-02-09 | $25.69M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2020-03-31 | $6.99M 10-Q · filed 2021-04-30 | $12.64M derived: sum of 2 quarters · filed 2022-02-09 | $20.70M derived: sum of 3 quarters · filed 2022-02-09 | $27.14M derived: sum of 4 quarters · filed 2022-02-09 | |||
| 2019-12-31 | $5.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $13.71M derived: sum of 2 quarters · filed 2022-02-09 | $20.15M derived: sum of 3 quarters · filed 2022-02-09 | $25.50M 10-K · filed 2022-02-09 | |||
| 2019-09-30 | $8.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $14.50M derived: sum of 2 quarters · filed 2020-10-30 | $19.85M 10-Q · filed 2020-10-30 | ||||
| 2019-06-30 | $6.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $11.79M 10-Q · filed 2020-07-31 | |||||
| 2019-03-31 | $5.35M 10-Q · filed 2020-05-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |